News | Halozyme
WEBHalozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below: Press Releases.
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEB6 days ago · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
Halozyme Announces Positive Clinical Data of its High-Volume …
WEBOct 16, 2023 · Halozyme, a biopharmaceutical company, demonstrates rapid subcutaneous delivery of 10 mL biologic with its ENHANZE drug delivery technology and high-volume auto-injector (HVAI). The study shows...
Halozyme Announces Positive Clinical Data of its High-Volume …
WEBOct 16, 2023 · Halozyme announces positive clinical data of its high-volume auto-injector that can deliver 10 mL of biologic products in 30 seconds. The company's ENHANZE drug delivery technology uses a...
Halozyme Therapeutics, Inc. (HALO) Latest Stock News
WEBGet the latest Halozyme Therapeutics, Inc. (HALO) stock news and headlines to help you in your trading and investing decisions.
Halozyme to Acquire Antares Pharma to Create a Specialty …
WEBApr 13, 2022 · Halozyme Therapeutics and Antares Pharma announce a definitive agreement for Halozyme to acquire Antares for $960 million in cash. The transaction will create a leading drug delivery and...
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND …
WEBAug 6, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2024, and provided an update...
Halozyme Completes Antares Pharma Acquisition - PR Newswire
WEBMay 24, 2022 · Halozyme Therapeutics, Inc. announces the successful completion of its acquisition of Antares Pharma, Inc., a biopharmaceutical company with a portfolio of injectable products. The merger aims...
Halozyme Therapeutics Agrees to Buy Antares Pharma
WEBApr 13, 2022 · HALO -3.01% Halozyme Therapeutics Inc. HALO -3.01% agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug...
Reinventing the patient experience. | Halozyme
WEBThe patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes.